Fig. 1From: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization studyChange in LDLC from entry to 28, 42, and 52Â weeks on Alirocumab 75Â mg every 2Â weeks in 29 patients; median, 25th and 75th LDLC percentiles displayedBack to article page